{"analyses":[{"ciLowerLimit":"0.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.25","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.8174","paramType":"Hazard Ratio (HR)","paramValue":"0.97","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.44","upperLimit":"22.21","value":"16.39"},{"groupId":"OG001","lowerLimit":"14.95","upperLimit":"24.21","value":"19.15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"175"}],"units":"Participants"}],"description":"The OS is defined as the time from the date of randomization to date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to this arm received the study drug, tivozanib hydrochloride.","id":"OG000","title":"Tivozanib Hydrochloride"},{"description":"Participants randomized to this arm received the comparator drug, sorafenib.","id":"OG001","title":"Sorafenib"}],"paramType":"MEDIAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"Date of randomization to date of death (up to approximately 5 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}